Anne-Vibeke Lænkholm1, Maj-Britt Jensen2, Jens Ole Eriksen3, Anne Roslind4, Wesley Buckingham5, Sean Ferree5, Torsten Nielsen6, Bent Ejlertsen7. 1. Department of Surgical Pathology, Zealand University Hospital, Slagelse, Denmark. Electronic address: anlae@regionsjaelland.dk. 2. Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark. 3. Department of Surgical Pathology, Zealand University Hospital, Slagelse, Denmark. 4. Department of Pathology, Herlev and Gentofte Hospital, Herlev, Denmark. 5. NanoString Technologies Inc, Seattle, WA. 6. Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada. 7. Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; Department of Oncology, Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark.
Abstract
PURPOSE: The Prosigna-PAM50 risk of recurrence (ROR) score has documented clinical utility for the prediction of 10-year distant recurrence (DR). The present study investigated the value of Prosigna-PAM50 for predicting 10-year DR and overall survival after 5 years of endocrine treatment for postmenopausal patients with invasive lobular carcinoma. PATIENTS AND METHODS: Using the Danish Breast Cancer Group database, we identified patients with a diagnosis from 2000 to 2003 of estrogen receptor-positive, human epidermal growth factor receptor 2-negative invasive ductal (n = 1570) or lobular (n = 341) cancer > 20 mm or 1 to 3 positive lymph nodes and applied multivariate Cox models. RESULTS: The median follow-up for DR was 9.3 years and for overall survival 15.2 years. Of the 341 lobular and 1570 ductal cases, 140 (41%) and 349 (22%) were classified as low ROR, with a 10-year DR rate of 7.7% (95% confidence interval [CI], 3.7%-13.6%) and 3.5% (95% CI, 1.8%-6.2%), respectively. The 10-year DR rate for the intermediate ROR group for those with lobular cancer was 18% (95% CI, 10.1%-27.9%) compared with 9.7% (95% CI, 6.7%-13.4%) for those with ductal cancer. Luminal B tumors had a significantly worse outcome than luminal A tumors in both lobular (hazard ratio, 1.89; 95% CI, 1.03%-3.45%; P = .04) and ductal (hazard ratio, 3.18; 95% CI, 2.29%-4.43%; P < .0001) cancer. CONCLUSION: Prosigna PAM-50 provides significant prognostic information beyond the clinicopathologic factors in patients with invasive lobular breast cancer. Those with lobular cancer had worse 10-year DR rates compared with those with ductal cancer in the same ROR category. Our results could have an effect on the treatment decisions regarding the addition of chemotherapy for those in the intermediate ROR group.
PURPOSE: The Prosigna-PAM50 risk of recurrence (ROR) score has documented clinical utility for the prediction of 10-year distant recurrence (DR). The present study investigated the value of Prosigna-PAM50 for predicting 10-year DR and overall survival after 5 years of endocrine treatment for postmenopausal patients with invasive lobular carcinoma. PATIENTS AND METHODS: Using the Danish Breast Cancer Group database, we identified patients with a diagnosis from 2000 to 2003 of estrogen receptor-positive, humanepidermal growth factor receptor 2-negative invasive ductal (n = 1570) or lobular (n = 341) cancer > 20 mm or 1 to 3 positive lymph nodes and applied multivariate Cox models. RESULTS: The median follow-up for DR was 9.3 years and for overall survival 15.2 years. Of the 341 lobular and 1570 ductal cases, 140 (41%) and 349 (22%) were classified as low ROR, with a 10-year DR rate of 7.7% (95% confidence interval [CI], 3.7%-13.6%) and 3.5% (95% CI, 1.8%-6.2%), respectively. The 10-year DR rate for the intermediate ROR group for those with lobular cancer was 18% (95% CI, 10.1%-27.9%) compared with 9.7% (95% CI, 6.7%-13.4%) for those with ductal cancer. Luminal B tumors had a significantly worse outcome than luminal A tumors in both lobular (hazard ratio, 1.89; 95% CI, 1.03%-3.45%; P = .04) and ductal (hazard ratio, 3.18; 95% CI, 2.29%-4.43%; P < .0001) cancer. CONCLUSION: Prosigna PAM-50 provides significant prognostic information beyond the clinicopathologic factors in patients with invasive lobular breast cancer. Those with lobular cancer had worse 10-year DR rates compared with those with ductal cancer in the same ROR category. Our results could have an effect on the treatment decisions regarding the addition of chemotherapy for those in the intermediate ROR group.
Authors: Jason A Mouabbi; Amy Hassan; Bora Lim; Gabriel N Hortobagyi; Debasish Tripathy; Rachel M Layman Journal: Breast Cancer Res Treat Date: 2022-03-26 Impact factor: 4.872
Authors: Matthias Christgen; Leonie Donata Kandt; Wiebke Antonopoulos; Stephan Bartels; Mieke R Van Bockstal; Martin Bredt; Maria Jose Brito; Henriette Christgen; Cecile Colpaert; Bálint Cserni; Gábor Cserni; Maximilian E Daemmrich; Raihanatou Danebrock; Franceska Dedeurwaerdere; Carolien Hm van Deurzen; Ramona Erber; Christine Fathke; Henning Feist; Maryse Fiche; Claudia Aura Gonzalez; Natalie D Ter Hoeve; Loes Kooreman; Till Krech; Glen Kristiansen; Janina Kulka; Florian Laenger; Marcel Lafos; Ulrich Lehmann; Maria Dolores Martin-Martinez; Sophie Mueller; Enrico Pelz; Mieke Raap; Alberto Ravarino; Tanja Reineke-Plaass; Nora Schaumann; Anne-Marie Schelfhout; Maxim De Schepper; Jerome Schlue; Koen Van de Vijver; Wim Waelput; Axel Wellmann; Monika Graeser; Oleg Gluz; Sherko Kuemmel; Ulrike Nitz; Nadia Harbeck; Christine Desmedt; Giuseppe Floris; Patrick Wb Derksen; Paul J van Diest; Anne Vincent-Salomon; Hans Kreipe Journal: J Pathol Clin Res Date: 2021-12-10
Authors: Johan Staaf; Jari Häkkinen; Cecilia Hegardt; Lao H Saal; Siker Kimbung; Ingrid Hedenfalk; Tonje Lien; Therese Sørlie; Bjørn Naume; Hege Russnes; Rachel Marcone; Ayyakkannu Ayyanan; Cathrin Brisken; Rebecka R Malterling; Bengt Asking; Helena Olofsson; Henrik Lindman; Pär-Ola Bendahl; Anna Ehinger; Christer Larsson; Niklas Loman; Lisa Rydén; Martin Malmberg; Åke Borg; Johan Vallon-Christersson Journal: NPJ Breast Cancer Date: 2022-08-16